|
AstraZeneca, Ardelyx to Collaborate on Novel NHE3-Inhibitor Drugs
AstraZeneca (AZ) has agreed to help shepherd Ardelyx’s NHE3-inhibitor program and primary Phase II compound to commercialization, promising to provide the California startup with as much as $272.5 million if new drugs are developed for certain bowel, kidney and renal disorders.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives